Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome
연구 개요
The goal of this phase IV, open-label, randomized clinical trial is to evaluate whether intravenous iron improves quality of life in adults aged 65 years and older with iron deficiency after an acute coronary syndrome (ACS). The main questions it aims to answer are: * Does intravenous iron improve quality of life at 6 and 12 months? * Does it reduce frailty and adverse clinical outcomes? Researchers will compare intravenous ferric carboxymaltose with standard of care. Participants will: * Be randomly assigned to receive intravenous iron or standard care * Attend three study visits over 12 months * Complete questionnaires and undergo blood tests
- 스폰서
- 협력: 아스트라제네카
- 적응증
- Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)
- 중재
- Ferric Carboxymaltose Injection [Ferinject]
- 목표 등록
- 538명
- 시작일
- 2026-03-05
- 완료(예정)
- 2028-05-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.